Enbezotinib
- Generic Name
- Enbezotinib
Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations
Phase 1
Terminated
- Conditions
- Advanced Solid TumorNon Small Cell Lung CancerMetastatic Solid TumorMedullary Thyroid CancerRET Gene Mutation
- Interventions
- First Posted Date
- 2019-11-13
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Turning Point Therapeutics, Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT04161391
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Local Institution - 2120, Houston, Texas, United States
🇺🇸Baylor College of Medicine - Baylor Heart Clinic, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath